Patents Assigned to ImmuLogic Pharmaceutical Corporation
  • Patent number: 6982326
    Abstract: The present invention provides nucleic acid sequences coding for the Cryptomeria japonica major pollen allergen Cry j I, Cry j II, Jun s I and Jun v I and fragments or peptides thereof. The present invention also provides purified Cry j I, Cry j II, Jun s I and Jun v I and at least one fragment thereof produced in a host cell transformed with a nucleic acid sequence coding for Cry j I, Cry j II, Jun s I and Jun v I or at least one fragment thereof, and fragments of Cry j I, Cry j II, Jun s I or Jun v I or at least one fragment thereof, and fragments of Cry j I, Cry j II, Jun s I or Jun v I prepared synthetically. Cry j I, Cry j II, Jun s I and Jun v I and fragments thereof are useful for diagnosing, treating, and preventing Japanese cedar pollinosis. The present invention also provides isolated peptides of Cry j I and Cry j II. Peptides within the scope of the invention comprise at least one T cell epitope, or preferably at least two T cell epitopes of Cry j I or Cry j II.
    Type: Grant
    Filed: January 29, 1999
    Date of Patent: January 3, 2006
    Assignee: ImmuLogic Pharmaceutical Corporation
    Inventors: Irwin J. Griffith, Joanne Pollock, Julian F. Bond, Richard D. Garman, Mei-chang Kuo, Stephen P. Powers, Mark A. Exley, Xian Chen, Ze'ev Shaked
  • Patent number: 6759234
    Abstract: The present invention provides therapeutic compositions and methods for treating disease conditions in humans associated with an antigen specific immune response by the human to an antigen such as a protein antigen (i.e. allergy and autoimmune diseases). Therapeutic compositions of the invention are reproducible preparations which are suitable for human therapy. Compositions of the invention comprise at least one isolated peptide having a defined sequence of amino acid residues and the composition is capable of down regulating an antigen specific immune response to an offending antigen in a population of humans subject to the antigen specific immune response. Compositions and methods of the invention may be used to treat sensitivity to protein allergens in humans and may also be used to treat autoimmune disease such as rheumatoid arthritis, diabetes, myasthenia gravis, Grave's disease, Good Pasture's syndrome, thyroiditis and multiple sclerosis.
    Type: Grant
    Filed: September 2, 1994
    Date of Patent: July 6, 2004
    Assignee: Immulogic Pharmaceutical Corporation
    Inventors: Malcolm L. Gefter, Ze′ev Shaked, Malcolm Morville
  • Patent number: 6689876
    Abstract: Isolated DNA encoding allergens of Dermatophagoides (house dust mites) particularly of the species Dermatophagoides farinae and Dermatophagoides pteronyssinus, which are protein allergens or peptides which include at least one epitope of the protein allergen. In particular, DNA encoding two major D. farinae allergens, Der f I and Der f II and DNA encoding a D. pteronyssinus allergen, Der p I. In addition, the proteins or peptides encoded by the isolated DNA, their use as diagnostic and therapeutic reagents and methods of diagnosing and treating sensitivity to house dust mite allergens.
    Type: Grant
    Filed: December 29, 1993
    Date of Patent: February 10, 2004
    Assignee: Immulogic Pharmaceutical Corporation
    Inventors: Wayne Robert Thomas, Kaw-Yan Chua
  • Patent number: 6489118
    Abstract: Isolated nucleic acids encoding allergens of Canis familiaris, Canf I or Can f II, are disclosed. A cDNA encoding a peptide having a Can f I activity and a predicted molecular weight of about 19,200 daltons is also described. A cDNA encoding a peptide having Can f II activity and a predicted molecular weight of about 18,200 daltons is also disclosed. The nucleic acids can be used as probes to detect the presence of Can f I or Can f II nucleic acid in a sample or for the recombinant production of petides having a Can f I or Can f II activity. Peptides having a Can f I or Can f II activity can be used in compositions suitable for pharmaceutical administration or methods of diagnosing sensitivity to dog dander.
    Type: Grant
    Filed: August 16, 1999
    Date of Patent: December 3, 2002
    Assignee: ImmuLogic Pharmaceutical Corporation
    Inventors: Jay P. Morgenstern, Christine B. Bizinkauskas, Andrzej Konieczny, Andrew W. Brauer
  • Patent number: 6413738
    Abstract: Isolated nucleic acids encoding allergens of the species Dermatophagoides pteronyssinus and Dermatophagoides farinae, Der p VII and Der f VII, respectively, are disclosed. A cDNA encoding a peptide having a Der p VII activity and a predicted molecular weight of about 22, 177 daltons is described. A cDNA encoding a peptide having Der f VII activity is also described. The nucleic acids of the invention can be used as probes to detect the presence of Der p VII or Der f VII nucleic acid in a sample or for the recombinant production of peptides having a Der p VII or Der f VII activity. Peptides having a Der p VII or Der f VII activity can be used in compositions suitable for pharmaceutical administration or methods of diagnosing sensitivity to house dust mite allergens.
    Type: Grant
    Filed: June 10, 1996
    Date of Patent: July 2, 2002
    Assignee: ImmuLogic Pharmaceutical Corporation
    Inventors: Wayne Robert Thomas, Kaw-Yan Chua
  • Publication number: 20020012963
    Abstract: Isolated nucleic acids encoding allergens of Canis familiaris, Canf I or Can f II, are disclosed. A cDNA encoding a peptide having a Can f I activity and a predicted molecular weight of about 19,200 daltons is also described. A cDNA encoding a peptide having Can f II activity and a predicted molecular weight of about 18,200 daltons is also disclosed. The nucleic acids can be used as probes to detect the presence of Can f I or Can f II nucleic acid in a sample or for the recombinant production of petides having a Can f I or Can f II activity. Peptides having a Can f I or Can f II activity can be used in compositions suitable for pharmaceutical administration or methods of diagnosing sensitivity to dog dander.
    Type: Application
    Filed: August 16, 1999
    Publication date: January 31, 2002
    Applicant: ImmuLogic Pharmaceutical Corporation
    Inventors: JAY P. MORGENSTERN, CHRISTINE B. BIZINKAUSKAS, ANDRZEJ KONIECZNY, ANDREW W. BRAUER
  • Patent number: 6268491
    Abstract: The present invention provides isolated peptides of the major protein allergens of the genus Dermatophagoides. Peptides within the scope of the invention comprises at least one T cell epitope, or preferably at least two T cell epitopes of a protein allergen selected from the allergens Der p I, Der p II, Der f I, or Der f II. The invention also pertains to modified peptides having similar or enhanced therapeutic properties as the corresponding, naturally-occurring allergen or portion thereof, but having reduced side effects. The invention further provides nucleic acid sequences coding for peptides of the invention. Methods of treatment or of diagnosis of sensitivity to house dust mites in an individual and therapeutic compositions comprising one or more peptides of the invention are also provided.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: July 31, 2001
    Assignee: ImmuLogic Pharmaceutical Corporation
    Inventors: Richard D. Garman, Julia L. Greenstein, Mei-chang Kuo, Bruce L. Rogers, Henry M. Franzen, Xian Chen, Sean Evans, Ze′ev Shaked
  • Patent number: 6147201
    Abstract: Isolated DNA encoding allergens of Dermatophagoides (house dust mites) particularly of the species Dermatophagoides farinae and Dermatophagoides pteronyssinus, which are protein allergens or peptides which include at least one epitope of the protein allergen. In particular, DNA encoding two major D. farinae allergens, Der f I and Der f II and DNA encoding a D. pteronyssinus allergen, Der p I. In addition, the proteins or peptides encoded by the isolated DNA, their use as diagnostic and therapeutic reagents and methods of diagnosing and treating sensitivity to house dust mite allergens.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: November 14, 2000
    Assignee: ImmuLogic Pharmaceutical Corporation
    Inventors: Wayne Robert Thomas, Geoffrey A. Stewart, Keven J. Turner, Richard J. Simpson
  • Patent number: 6120769
    Abstract: A substantially pure, covalently linked human T cell reactive feline protein (TRFP) has been isolated from vacuum bag extract obtained by affinity purification of house dust collected from several homes with cats; DNA encoding all or a portion of the TRFP or peptide; compositions containing such a protein or peptide or portions thereof; and antibodies reactive with the TRFP or peptide are disclosed. Also disclosed are recombinant TRFP or peptide; modified or mutated TRFP peptides; their use for diagnostic or therapeutic purposes.
    Type: Grant
    Filed: April 28, 1995
    Date of Patent: September 19, 2000
    Assignee: ImmuLogic Pharmaceutical Corporation
    Inventors: Malcolm L. Gefter, Richard D. Garman, Julia L. Greenstein, Julian F. Bond
  • Patent number: 6086897
    Abstract: Isolated DNA encoding allergens of Dermatophagoides (house dust mites) particularly of the species Dermatophagoides farinae and Dermatophagoides pteronyssinus, which are protein allergens or peptides which include at least one epitope of the protein allergen. In particular, DNA encoding two major D. farinae allergens, Der f I and Der f II and DNA encoding a D. pteronssinus allergen, Der p I. In addition, the proteins or peptides encoded by the isolated DNA, their use as diagnostic and therapeutic reagents and methods of diagnosing and treating sensitivity to house dust mite allergens.
    Type: Grant
    Filed: June 5, 1995
    Date of Patent: July 11, 2000
    Assignee: ImmuLogic Pharmaceutical Corporation
    Inventors: Wayne Robert Thomas, Kaw-Yan Chua
  • Patent number: 6077518
    Abstract: Isolated allergens of Dermatophagoides (house dust mites) particularly of the species and Dermatophagoides pteronyssinus, which are protein allergens or peptides which include at least one epitope of the protein allergen. In addition, the or peptides encoded by the isolated DNA, their use as diagnostic and therapeutic reagents and methods of diagnosing and treating sensitivity to house dust mite allergens.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: June 20, 2000
    Assignee: ImmuLogic Pharmaceutical Corporation
    Inventors: Wayne Robert Thomas, Geoffrey Alexander Stewart, Keven Turner, Richard John Simpson
  • Patent number: 6060057
    Abstract: Isolated DNA encoding allergens of Dermatophagoides (house dust mites) particularly of the species Dermatophagoides farinae and Dermatophagoides pteronyssinus, which are protein allergens or peptides which include at least one epitope of the protein allergen. In particular, DNA encoding two major D. farinae allergens, Der f I and Der f II and DNA encoding a D. pteronyssinus allergen, Der p I. In addition, the proteins or peptides encoded by the isolated DNA, their use as diagnostic and therapeutic reagents and methods of diagnosing and treating sensitivity to house dust mite allergens.
    Type: Grant
    Filed: June 5, 1995
    Date of Patent: May 9, 2000
    Assignee: ImmuLogic Pharmaceutical Corporation
    Inventors: Wayne Robert Thomas, Kaw-Yan Chua
  • Patent number: 6054127
    Abstract: Hapten-carrier conjugates capable of eliciting anti-hapten antibodies in vivo are disclosed. Methods of preparing the hapten-carrier conjugates and therapeutic compositions are also disclosed. Where the hapten is a drug of abuse, a therapeutic composition containing the hapten-carrier conjugate is particularly useful in the treatment of drug addiction, more particularly, cocaine addiction. Passive immunization using antibodies raised against conjugates of the instant invention is also disclosed. The therapeutic composition is suitable for co-therapy with other conventional drugs.
    Type: Grant
    Filed: June 27, 1997
    Date of Patent: April 25, 2000
    Assignee: Immulogic Pharmaceutical Corporation
    Inventors: Philip A. Swain, Victoria C. Schad, Julia L. Greenstein, Mark A. Exley, Barbara S. Fox, Stephen P. Powers, Malcolm L. Gefter, Thomas J. Briner
  • Patent number: 6048962
    Abstract: A substantially pure, covalently linked human T cell reactive feline protein (TRFP) has been isolated from vacuum bag extract obtained by affinity purification of house dust collected from several homes with cats; DNA encoding all or a portion of the TRFP or peptide; compositions containing such a protein or peptide or portions thereof; and antibodies reactive with the TRFP or peptide are disclosed. Also disclosed are recombinant TRFP or peptide; modified or mutated TRFP peptides; their use for diagnostic or therapeutic purposes.
    Type: Grant
    Filed: April 27, 1995
    Date of Patent: April 11, 2000
    Assignee: Immulogic Pharmaceutical Corporation
    Inventors: Malcolm L. Gefter, Richard D. Garman, Julia L. Greenstein, Mei-chang Kuo, Bruce L. Rogers, Irwin J. Griffith, Jay P. Morgenstern, Andrew W. Brauer
  • Patent number: 6025162
    Abstract: A substantially pure, covalently linked human T cell reactive feline protein (TRFP) has been isolated from vacuum bag extract obtained by affinity purification of house dust collected from several homes with cats; DNA encoding all or a portion of the TRFP or peptide; compositions containing such a protein or peptide or portions thereof; and antibodies reactive with the TRFP or peptide are disclosed. Also disclosed are recombinant TRFP or peptide; modified or mutated TRFP peptides; their use for diagnostic or therapeutic purposes.
    Type: Grant
    Filed: April 28, 1995
    Date of Patent: February 15, 2000
    Assignee: Immulogic Pharmaceutical Corporation
    Inventors: Bruce L. Rogers, Irwin J. Griffith, Jay P. Morgenstern
  • Patent number: 6019972
    Abstract: A substantially pure, covalently linked human T cell reactive feline protein (TRFP) has been isolated from vacuum bag extract obtained by affinity purification of house dust collected from several homes with cats; DNA encoding all or a portion of the TRFP or peptide; compositions containing such a protein or peptide or portions thereof; and antibodies reactive with the TRFP or peptide are disclosed. Also disclosed are recombinant TRFP or peptide; modified or mutated TRFP peptides; their use for diagnostic or therapeutic purposes.
    Type: Grant
    Filed: September 2, 1994
    Date of Patent: February 1, 2000
    Assignee: ImmuLogic Pharmaceutical Corporation
    Inventors: Malcolm L. Gefter, Richard D. Garman, Julia L. Greenstein, Mei-chang Kuo, Malcolm Morville, Thomas J. Briner
  • Patent number: 5973132
    Abstract: Isolated DNA encoding allergens of Dermatophagoides (house dust mites) particularly of the species Dermatophagoides farinae and Dermatophagiodes pteronyssinus, which are protein allergens or peptides which include at least one epitope of the protein allergen. In particular, DNA encoding two major D. farinae allergens, Der f I and Der f II and DNA encoding a D. pteronyssinus allergen, Der p II. In addition, the proteins or peptides encoded by the isolated DNA, their use as diagnostic and therapeutic reagents and methods of diagnosing and treating sensitivity to house dust mite allergens.
    Type: Grant
    Filed: June 2, 1995
    Date of Patent: October 26, 1999
    Assignee: ImmuLogic Pharmaceutical Corporation
    Inventors: Wayne Robert Thomas, Geoffrey Alexander Stewart, Keven Turner, Richard John Simpson
  • Patent number: 5939283
    Abstract: Isolated nucleic acids encoding allergens of Canis familiaris, Can f I or Can f II, are disclosed. A cDNA encoding a peptide having a Can f I activity and a predicted molecular weight of about 19,200 daltons is also described. A cDNA encoding a peptide having Can f II activity and a predicted molecular weight of about 18,200 daltons is also disclosed. The nucleic acids can be used as probes to detect the presence of Can f I or Can f II nucleic acid in a sample or for the recombinant production of peptides having a Can f I or Can f II activity. Peptides having a Can f I or Can f II activity can be used in compositions suitable for pharmaceutical administration or methods of diagnosing sensitivity to dog dander.
    Type: Grant
    Filed: October 27, 1995
    Date of Patent: August 17, 1999
    Assignee: ImmuLogic Pharmaceutical Corporation
    Inventors: Jay P. Morgenstern, Christine B. Bizinkauskas, Andrzej Koniecsny, Andrew W. Brauer
  • Patent number: 5891716
    Abstract: Isolated nucleic acids encoding allergens of Canis familiaris, Can f I or Can f II, are disclosed. A cDNA encoding a peptide having a Can f I activity and a predicted molecular weight of about 19,200 daltons is also described. A cDNA encoding a peptide having Can f II activity and a predicted molecular weight of about 18,200 daltons is also disclosed. The nucleic acids can be used as probes to detect the presence of Can f I or Can f II nucleic acid in a sample or for the recombinant production of petides having a Can f I or Can f II activity. Peptides having a Can f I or Can f II activity can be used in compositions suitable for pharmaceutical administration or methods of diagnosing sensitivity to dog dander.
    Type: Grant
    Filed: June 6, 1995
    Date of Patent: April 6, 1999
    Assignee: ImmuLogic Pharmaceutical Corporation
    Inventors: Jay P. Morgenstern, Andrzej Konieczny, Christine B. Bizinkauskas, Andrew W. Brauer
  • Patent number: 5876727
    Abstract: Hapten-carrier conjugates capable of eliciting anti-hapten antibodies in vivo are disclosed. Methods of preparing the hapten-carrier conjugates and therapeutic compositions are also disclosed. Where the hapten is a drug of abuse, a therapeutic composition containing the hapten-carrier conjugate is particularly useful in the treatment of drug addiction, more particularly, cocaine addiction. Passive immunization using antibodies raised against conjugates of the instant invention is also disclosed. The therapeutic composition is suitable for co-therapy with other conventional drugs.
    Type: Grant
    Filed: September 30, 1996
    Date of Patent: March 2, 1999
    Assignee: ImmuLogic Pharmaceutical Corporation
    Inventors: Philip A. Swain, Victoria C. Schad, Julia L. Greenstein, Mark A. Exley, Barbara S. Fox, Stephen P. Powers, Malcolm L. Gefter